BenevolentAI SPAC Presentation Deck
Advanced laboratory capabilities help move programmes
faster, and generate data at scale for continuous innovation
Advanced capabilities
and technologies
• Fully equipped laboratory facilities; Biology,
Chemistry, CMC, DMPK. Highly experienced
scientists across all drug discovery disciplines
• In-house investment in CRISPR, RNA seq and
human IPSC capabilities
• Robust and secure data storage capacity
. Access to the Babraham Institute Research
facility, with state of the art High Content
Imaging and FACS capabilities.
• CROS and academic collaborations
complement and extend internal capabilities
Cambridge,
The Babraham Institute
Campus
Experimental capabilities enhance
entire drug discovery process
• Mechanism selection, Target identification,
target triage and experimental validation
Refined, model-enabled Design-Make-Test
cycle
Closing the data loop
• Experimental data from hypothesis validation
workflows, portfolio projects and disease
relevant expression data are integrated back
to further enrich the knowledge graph and
our representation of human biology
Work progresses rapidly from in-silico to in-vitro experimental test
✔ Dynamic experimental feedback loop between scientists & technologists
Benevolent 15View entire presentation